SHR-1894
/ Jiangsu Hengrui Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
February 18, 2026
A Phase I Study of Single Subcutaneous Dose of SHR-1894 in Healthy Subjects
(clinicaltrials.gov)
- P1 | N=40 | Not yet recruiting | Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
New P1 trial • Dermatitis • Dermatology • Immunology
1 to 1
Of
1
Go to page
1